Cancer-associated tert promoter mutations abrogate telomerase silencing

eLife

Volumn 4, Issue JULY 2015, 2015, Pages 1-20

  Chiba, Kunitoshi ^a   Johnson, Joshua Z ^a   Vogan, Jacob M ^a   Wagner, Tina ^a   Boyle, John M ^a   Hockemeyer, Dirk ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; OCTAMER TRANSCRIPTION FACTOR 4; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TERT PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; NEOPLASM; NERVE CELL DIFFERENTIATION; NORTHERN BLOTTING; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; GENETICS; MUTATION; PHYSIOLOGY; PROMOTER REGION;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MUTATION; PLURIPOTENT STEM CELLS; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84937408885     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.07918     Document Type: Article

References (51)

1. Armanios M, Blackburn E H. 2012. The telomere syndromes. Nature Reviews. Genetics 13:693–704. doi:10.1038/nrg3246
2. Armanios M, Price C. 2012. Telomeres and disease: an overview. Mutation Research 730:1–2. doi:10.1016/jmrfmmm.2011.11.005
3. Aubert G. 2014. Telomere dynamics and aging. Progress in Molecular Biology and Translational Science 125: 89–111. doi:10.1016/B978-0-12-397898-1.00004-9
4. Aubert G, Baerlocher GM, Vulto I, Poon SS, Lansdorp PM. 2012. Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes. PLOS Genetics 8:e1002696. doi:101371/journal.pgen.1002696
5. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608–611 doi:10.1038/nature07602.
6. Batista LF, Artandi SE. 2013. Understanding telomere diseases through analysis of patient-derived iPS cells Current Opinion in Genetics & Development 23:526–533. doi:10.1016/j.gde.2013.07.006
7. Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaug AJ, Crary SM, Choi J, Sebastiano V, Cherry A, Giri N, Wernig M, Alter BP, Cech TR, Savage SA, Reijo Pera RA, Artandi SE. 2011. Telomere shortening and loss of selfrenewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474:399–402. doi:10.1038/nature10084
8. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SF, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, Walsh KM, Myong S, Song JS, Costello JF. 2015. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348:1036–1039. doi:10.1126/science.aab0015
9. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352 doi:10.1126/science.279.5349.349
10. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F, Australian Cancer Study, Australian Ovarian Cancer Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Gene Environment Interaction and Breast Cancer (GENICA), Swedish Breast Cancer Study (SWE-BRCA), Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE), Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Vergote I, Lambrechts S, Despierre E, Risch HA, Gonza´ lez-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Du¨ rst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Do¨ rk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch- Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlow I, Blomqvist C, Rodriguez-Rodriguez L, Aittoma¨ ki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeney LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Mu¨ ller H, Arndt V, Labre` che F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth- Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Bru¨ ning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylka¨ s K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsan P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Colle´ e JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux- Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. 2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics 45: 371–384. 384e371-372. doi: 10.1038/ng.2566. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. 2015. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347:1006–1010. doi:10.1126/science.1260200
11. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. 2009. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology 27:275–280 doi:10.1038/nbt.1529
12. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM. 1996. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 14:239–248 doi:10.1002/stem.140239
13. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. doi:10.1126/science.1231143
14. Counter CM. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. The EMBO Journal 11:1921–1929
15. Cristofari G, Lingner J. 2006. Telomere length homeostasis requires that telomerase levels are limiting. The EMBO Journal 25:565–574. doi:10.1038/sj.emboj.7600952
16. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. 2002. Regulation of the human telomerase reverse transcriptase gene. Oncogene 21:541–552. doi:10.1038/sj.onc.1205081
17. Fredriksson NJ, Ny L, Nilsson JA, Larsson E. 2014. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics 46:1258–1263. doi:10.1038/ng.3141
18. Fu D, Collins K. 2003. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs Molecular Cell 11:1361–1372. doi:10.1016/S1097-2765(03)00196-5
19. Greenberg RA, O’Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, DePinho RA 1999. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219–1226. doi:10.1038/sj.onc.1202669
20. Greider CW, Blackburn EH. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43:405–413. doi:10.1016/0092-8674(85)90170-9
21. Gunes C, Rudolph KL. 2013. The role of telomeres in stem cells and cancer. Cell 152:390–393. doi:10.1016/j.cell2013.01.010
22. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. 2014. TERT promoter mutations in cancer development Current Opinion in Genetics & Development 24:30–37. doi:10.1016/j.gde.2013.11.005
23. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proceedings of the National Academy of Sciences of USA 96:14276–14281. doi:10.1073/pnas.96.25.14276
24. Hockemeyer D, Sfeir AJ, Shay JW, Wright WE, de Lange T. 2005. POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. The EMBO Journal 24:2667–2678. doi:101038/sj.emboj.7600733
25. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, Meng X, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature Biotechnology 27: 851–857. doi:10.1038/nbt.1562
26. Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. 2008. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell 3:346–353. doi:10.1016/j.stem.200808.014
27. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. 2011. Genetic engineering of human pluripotent cells using TALE nucleases. Nature Biotechnology 29:731–734. doi:10.1038/nbt.1927
28. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961. doi:101126/science.1230062
29. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959. doi:10.1126/science.1229259
30. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821. doi:10.1126/science.1225829
31. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, IeM Shih, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. 2013. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences 110:6021–6026. doi:10.1073/pnas1303607110
32. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015 doi:10.1126/science.7605428
33. Kipling D, Cooke HJ. 1990. Hypervariable ultra-long telomeres in mice. Nature 347:400–402. doi:10.1038/347400a0
34. Kyo S, Takakura M, Fujiwara T, Inoue M. 2008. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Science 99:1528–1538. doi:10.1111/j.1349-7006.2008.00878.x.
35. Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Welstead GG, Alagappan R, Frampton GM, Xu P, Muffat J, Santagata S, Powers D, Barrett CB, Young RA, Lee JT, Jaenisch R, Mitalipova M. 2010 Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 141:872–883. doi:10.1016/j.cell.2010.04.010
36. Lin SY, Elledge SJ. 2003. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881–889 doi:10.1016/S0092-8674(03)00430-6
37. Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296. doi:10.1016/j.ccr.2012.03.003
38. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Munoz P, Clevers H, Sancho E, Mangues R, Batlle E. 2011. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8:511–524. doi:10.1016/jstem.2011.02.020
39. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White MA, Wright WE, Shay JW. 1999. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genetics 21:115–118 doi:10.1038/5063
40. Nakashima M, Nandakumar J, Sullivan KD, Espinosa JM, Cech TR. 2013. Inhibition of telomerase recruitment and cancer cell death. The Journal of Biological Chemistry 288:33171–33180. doi:10.1074/jbc.M113.518175
41. Palm W, de Lange T. 2008. How shelterin protects mammalian telomeres. Annual Review of Genetics 42:301–334 doi:10.1146/annurev.genet.41.110306.130350
42. Schepers AG, Vries R, van den Born M, van de Wetering M, Clevers H. 2011. Lgr5 intestinal stem cells have high telomerase activity and randomly segregate their chromosomes. The EMBO Journal 30:1104–1109. doi:10.1038/emboj.2011.26
43. Sexton AN, Regalado SG, Lai CS, Cost GJ, O’Neil CM, Urnov FD, Gregory PD, Jaenisch R, Collins K, Hockemeyer D. 2014. Genetic and molecular identification of three human TPP1 functions in telomerase action: recruitment, activation, and homeostasis set point regulation. Genes & Development 28:1885–1899. doi:10.1101/gad246819.114
44. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. 2009. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136:964–977. doi:10.1016/j.cell.2009.02.013
45. Strong MA, Vidal-Cardenas SL, Karim B, Yu H, Guo N, Greider CW. 2011. Phenotypes in mTERT(+)/(-) and mTERT (-)/(-) mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase Molecular and Cellular Biology 31:2369–2379. doi:10.1128/MCB.05312-11
46. Wege H, Chui MS, Le HT, Tran JM, Zern MA. 2003. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Research 31:E3–E3. doi:10.1093/nar/gng003
47. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. 2014. Genome-wide analysis of noncoding regulatory mutations in cancer. Nature Genetics 46:1160–1165. doi:10.1038/ng.3101
48. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. 1996. Telomerase activity in human germline and embryonic tissues and cells. Developmental Genetics 18:173–179. doi:10.1002/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3
49. Xu L, Blackburn EH. 2007. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres Molecular Cell 28:315–327. doi:10.1016/j.molcel.2007.10.005
50. Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson SP, Saretzki G, Armstrong L, Lako M 2008. A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. Stem Cells 26:850–863. doi:10.1634/stemcells.2007-0677
51. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. 2009. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Reviews. Drug Discovery 8:806–823. doi:10.1038/nrd2137